

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cofoe Medical Technology Co., Ltd.
可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1187)

**ANNOUNCEMENT ON CHANGE OF REGISTERED CAPITAL AND
AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The sixth meeting of the third session of the board of directors of Cofoe Medical Technology Co., Ltd. (the "**Company**") was held on June 5, 2026, at which the Proposal on Change of Registered Capital and Amendments to the Articles of Association was considered and approved. The details are hereby announced as follows:

I. CHANGE IN THE COMPANY'S REGISTERED CAPITAL

Following the completion of the issuance of H shares and the listing of such shares on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**"), the Company's total share capital and registered capital have changed. The details are as follows:

After filing with the China Securities Regulatory Commission and approved by the Hong Kong Stock Exchange, 27,000,000 H shares of the Company have been listed for trading on the Main Board of the Hong Kong Stock Exchange since May 6, 2026. The Company's total share capital was changed from 208,897,000 shares to 235,897,000 shares, and the registered capital was changed from RMB208,897,000 to RMB235,897,000.

II. AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In view of the above changes in the Company's registered capital and share capital, as well as the listing and trading of the Company's issued H shares on the Main Board of the Hong Kong Stock Exchange, the Company proposes to amend the relevant provisions of the Articles of Association. The comparison table before and after the amendment is set out as follows:

Article	Before amendments	After amendments
Article 3	<p>As approved by the Shenzhen Stock Exchange (the "SZSE"), and with the registration approval from the China Securities Regulatory Commission (the "CSRC") on August 2, 2021, the Company made initial public offering of 40,000,000 RMB-denominated ordinary shares which were listed on the SZSE on October 25, 2021.</p> <p>As filed with the CSRC on [•], and approved by The Stock Exchange of Hong Kong Limited on [•], the Company made initial public offering of [•] overseas listed foreign shares (the "H Shares") in Hong Kong before full exercise of over-allotment option, and H Shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on [•].</p>	<p>As approved by the Shenzhen Stock Exchange (the "SZSE"), and with the registration approval from the China Securities Regulatory Commission (the "CSRC") on August 2, 2021, the Company made initial public offering of 40,000,000 RMB-denominated ordinary shares which were listed on the SZSE on October 25, 2021.</p> <p>As filed with the CSRC on February 28, 2026, and approved by The Stock Exchange of Hong Kong Limited on May 5, 2026, the Company made initial public offering of 27,000,000 overseas listed foreign shares (the "H Shares") in Hong Kong, and H Shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on May 6, 2026.</p>
Article 6	The registered capital of the Company is RMB[•].	The registered capital of the Company is RMB235,897,000.

Article	Before amendments	After amendments
Article 17	After the completion of the initial public offering of H Shares (over-allotment option is not exercised/over-allotment option is exercised), the total number of the shares of the Company is [•], all of which are ordinary shares, including [•] A ordinary shares and [•] H ordinary shares.	After the completion of the initial public offering of H Shares, the total number of the shares of the Company is 235,897,000, all of which are ordinary shares, including 208,897,000 A ordinary shares and 27,000,000 H ordinary shares.
Article 202	Upon consideration and approval at the general meeting of the Company, the Articles of Association shall take effect and be implemented from the date on which overseas-listed H Shares issued by the Company through its initial public offering are listed on The Stock Exchange of Hong Kong Limited.	The Articles of Association shall take effect and be implemented from the date of consideration and approval at the general meeting of the Company.

Except for the above amendments, all other provisions of the Articles of Association shall remain unchanged. For full text of the Articles of Association, please refer to the relevant announcement disclosed by the Company on CNINFO (www.cninfo.com.cn) on the same day.

Pursuant to the authorisation granted by the second extraordinary general meeting of 2025 of the Company, the amendments to the Articles of Association are not subject to consideration at the general meeting of the Company. The board of directors of the Company has authorised the management of the Company to handle matters related to the registration or filing of relevant business changes, with the final changes subject to the registration or filing as approved by the business registration authority.

III. DOCUMENTS AVAILABLE FOR INSPECTION

Resolution of the sixth meeting of the third session of the board of directors of the Company.

This announcement is hereby made.

By order of the Board
Cofoe Medical Technology Co., Ltd.
Mr. ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, June 5, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive Directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive Directors.